Who Will Benefit From Bariatric Surgery for Diabetes?
Who Will Benefit From Bariatric Surgery for Diabetes? Using Fat Distribution Measurement, Gut Hormone Profiles and Genetic Data to Predict Diabetes Remission
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Julia S Kenkre, MB BChir
- Phone Number: +44208383242
- Email: imperial.bariatricstudy@nhs.net
Study Locations
-
-
Greater London
-
London, Greater London, United Kingdom, W12 0HS
- Recruiting
- Imperial College Healthcare NHS Trust
-
Contact:
- Julia S Kenkre, MB BChir
-
Principal Investigator:
- Tricia Tan, MB ChB
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Bariatric surgery group
Inclusion Criteria:
- Males and females planning to undergo RYGB
- 18-80 years
- Type 2 diabetes mellitus or prediabetes
- Stable weight for at least 3 months
- Obese (BMI ≥30kg/m2)
- Eligible for surgery on the National Health Service (NHS) under The National Institute for Health and Care Excellence (NICE) 2014 criteria
Exclusion Criteria:
- Current pregnancy
- Inability to give informed consent
- Type 1 diabetes
- Low fasting C-peptide
- Secondary diabetes or absence of β-cell function
- Unable to undergo DEXA, cirrhosis, ascites, or other condition that may modify body fat composition e.g. underlying malignancy
- Current smoker
- Participation in another (interventional) trial within the last 3 months
- Unable to understand English
Healthy volunteers
Inclusion criteria:
- Aged 18-80 years
- Male or female
- Body mass index 19 - 25 kg/m2
- Stable weight for at least three months
Exclusion criteria:
- Abnormal glucose tolerance and fasting glucose
- History of any medical, or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study
- Without access at home to a telephone, or other factor likely to interfere with ability to participate reliably in the study
- Pregnancy or breastfeeding
- Unable to maintain adequate contraception for the duration of the study
- Donated blood during the preceding 3 months or intention to do so before the end of the study
- Current smoker
- Participation in another trial within the last 3 months
- Unable to understand English
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Surgical cohort
Patients with type 2 diabetes undergoing Roux-en-Y gastric bypass surgery
|
Bariatric surgery
|
|
Control
Healthy volunteers with normal body mass index
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Diabetes remission (partial or complete)
Time Frame: 1 year
|
1 year
|
|
Diabetes remission (complete)
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weight loss
Time Frame: 1 year
|
1 year
|
|
|
Waist circumference, waist/hip ratio (cm)
Time Frame: 1 year
|
1 year
|
|
|
Body mass index (kg/m2)
Time Frame: 1 year
|
1 year
|
|
|
Change in visceral adipose tissue
Time Frame: 1 year
|
Dual Energy Xray Absorptiometry measurement (DEXA)
|
1 year
|
|
Change in visceral adipose tissue
Time Frame: 1 year
|
Magnetic resonance imaging (MRI) measurement
|
1 year
|
|
Change in ectopic fat
Time Frame: 1 year
|
MRI measurement
|
1 year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in epigenetic data in tissues.
Time Frame: 1 year
|
1 year
|
|
Changes in the transcriptome in tissues
Time Frame: 1 year
|
1 year
|
|
Changes in gut hormone profiles
Time Frame: 1 year
|
1 year
|
|
Histological scoring of specimens for Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis
Time Frame: 1 year
|
1 year
|
|
Changes in gut microbiome
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Tricia Tan, MB ChB, Imperial College London
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRAS:231300
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.